neck, chest, abdomen and pelvis). Metaiodobenzylguanidine (mIBG) scintigraphy is highly specific for pheochromocytomas and paragangliomas and also provides a guide to the therapeutic potential of ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback